Background Entecavir is a potent nucleoside analogue for treating chronic hepatitis B
(CHB). Quantitative hepatitis B surface antigen (qHBsAg) levels are predictive of response to …

Background The clinical value of quantitative hepatitis B surface antigen (qHBsAg) titre in
patients taking nucleotide/nucleoside analogues (NAs) is still controversial. This study aims …

Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and
association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving …

Objectives To assess off-treatment virological relapse rates and to determine the role of
hepatitis B surface antigen (HBsAg) quantification in predicting virological relapse after …

Results Twenty-eight patients were treated for a median period of 21 months (range: 18 to
24 mo). Serum HBsAg level showed a mean of 4.0, 3.7, and 3.6 log 10 IU/mL at …

OBJECTIVES: This study aims to assess whether quantitative HBsAg can predict durability
of chronic hepatitis B (CHB) patients stopping entecavir (ETV) treatment. METHODS: We …

Background/Purpose Several anti-viral drugs are approved for the treatment of hepatitis B
virus (HBV) infection. However, whether quantitative hepatitis B surface antigen (qHBsAg) …

AIM To investigate the utility of hepatitis B surface antigen (HBsAg) kinetics in chronic
hepatitis B patients during long-term entecavir treatment. METHODS This retrospective study …

Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen
(qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the …

OBJECTIVES: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients
receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response …